heparg
biopred
kindli
provid
dr
christoph
seeger
fox
chase
cancer
center
primari
human
hepatocyt
phh
phoenixbio
cultur
describ
hbv
use
studi
mainli
deriv
cultur
supernat
cell
hbv
infect
perform
describ
detail
procedur
given
support
inform
indirect
immunofluoresc
analysi
realtim
pcr
southern
blot
analysi
mtt
assay
report
assay
perform
essenti
detail
procedur
given
support
inform
hb
antigen
quantifi
enzymelink
immunosorb
assay
elisa
describ
hbe
antigen
detect
chemiluminesc
immunoassay
mitsubishi
chemic
medienc
hcv
pseudoparticl
hcvpp
reproduc
hcv
envelopemedi
entri
gener
transfect
express
plasmid
mlv
gagpol
hcv
luciferas
packag
virion
kindli
provid
dr
francoislo
cosset
univers
lyon
cell
hcvpp
recov
cultur
supernat
transfect
cell
use
hcv
entri
assay
describ
transport
activ
ntcp
assay
essenti
use
sekisui
medic
cell
perman
overexpress
human
ntcp
briefli
cell
preincub
compound
minut
incub
radiolabel
substrat
taurochol
acid
tca
minut
allow
substrat
uptak
cell
cell
wash
lyse
measur
accumul
radioact
assay
observ
cytotox
effect
compound
concentr
test
detail
procedur
given
support
inform
recombin
ntcp
hb
protein
tag
biotin
respect
synthes
use
wheat
cellfre
protein
system
describ
proteinprotein
interact
detect
use
alphascreen
igg
proteina
detect
kit
perkinelm
accord
manufactur
instruct
briefli
recombin
tag
protein
incub
streptavidinco
donor
bead
antibodyconjug
acceptor
bead
gener
luminesc
signal
brought
proxim
bind
interact
protein
luminesc
analyz
alphascreen
detect
program
envis
spectrophotomet
perkinelm
detail
procedur
alphascreen
assay
describ
support
inform
addit
experiment
procedur
includ
support
inform
focus
hbv
entri
establish
cell
cultur
system
evalu
step
hbv
infect
identifi
small
molecul
inhibit
hbv
entri
pretreat
heparg
compound
hour
ad
hbv
inoculum
continu
incub
compound
hour
fig
wash
free
hbv
compound
cell
cultur
addit
day
absenc
compound
fig
robust
chemic
screen
hbv
infect
monitor
viral
envelop
protein
hb
level
secret
infect
cell
day
postinfect
elisa
assay
could
identifi
heparin
hbv
attach
bafilomycin
vtype
h
atpas
inhibitor
block
acidif
vesicl
hbv
lamivudin
revers
transcriptas
compound
reduc
hb
protein
level
medium
fig
addit
use
antihb
antibodi
neutral
viral
entri
use
antiflag
antibodi
reduc
viral
protein
secret
hbvinfect
cell
fig
thu
system
like
evalu
effect
compound
earli
phase
hbv
life
cycl
includ
attach
entri
effect
hbv
replic
chemic
screen
system
reveal
csa
reduc
hb
secret
hbvinfect
cell
fig
treatment
csa
significantli
decreas
hbc
protein
express
fig
hbv
dna
well
cccdna
fig
cell
hbe
medium
fig
without
caus
cytotox
support
fig
effect
csa
limit
infect
heparg
cell
observ
similar
antihbv
effect
csa
phh
fig
antihbv
effect
csa
also
observ
hbv
infect
phh
absenc
fig
indic
effect
csa
depend
normal
includ
hbv
infect
experi
data
suggest
csa
block
hbv
infect
csa
decreas
hb
hbe
secret
infect
cell
dosedepend
manner
fig
next
investig
step
hbv
life
cycl
block
csa
hbv
life
cycl
divid
two
phase
earli
phase
infect
includ
attach
entri
nuclear
import
cccdna
format
follow
late
phase
repres
hbv
replic
includ
transcript
assembl
revers
transcript
viral
lamivudin
drastic
decreas
hbv
dna
reproduc
hbv
replic
earli
phase
infect
fig
addit
continu
treatment
lamivudin
well
entecavir
day
hbv
infect
could
decreas
hbv
dna
level
hbvinfect
heparg
cell
suggest
inhibit
hbv
replic
fig
nevertheless
lamivudin
show
antihbv
effect
appli
prior
hbv
infect
fig
b
suggest
antihbv
compound
identifi
fig
interrupt
earli
phase
hbv
life
cycl
examin
whether
csa
inhibit
attach
entri
evalu
hbv
cell
surfac
hbv
dna
extract
quantifi
heparg
cell
expos
hbv
hour
wash
fig
intern
cell
wash
cultur
hour
allow
hbv
intern
cell
trypsin
digest
hbv
remain
cell
surfac
allow
quantif
intern
hbv
dna
fig
csa
slightli
reduc
amount
attach
hbv
dna
although
effect
statist
signific
fig
contrast
csa
caus
signific
reduct
hbv
dna
intern
assay
fig
time
addit
assay
shown
fig
treatment
csa
hbv
infect
decreas
hb
hbe
product
fig
csa
antihbv
effect
deliv
hbv
infect
fig
thu
csa
appear
primarili
block
entri
step
includ
intern
examin
whether
csa
target
hbv
particl
host
cell
preincub
hbv
csa
purifi
csa
hbv
inoculum
follow
measur
hbv
infect
use
heparg
cell
fig
preincub
csa
affect
hbv
infect
contrast
antagon
effect
heparin
hbv
particl
fig
suggest
csa
affect
hbv
particl
rather
target
host
cell
examin
antihbv
effect
csa
infect
differ
genotyp
hbv
phh
shown
fig
csa
reduc
infect
hbv
genotyp
c
differ
sequenc
viru
strain
use
figur
howev
csa
affect
entri
hcv
contrast
inhibit
hcv
entri
heparin
bafilomycin
antihcv
antibodi
fig
csa
use
clinic
immunosuppress
patient
follow
liver
therefor
investig
activ
immunosuppress
hbv
infect
among
addit
immunosuppress
drug
examin
abl
suppress
hbv
infect
fig
csa
known
three
major
cellular
target
cellular
cyclophilin
cyp
calcineurin
cn
transport
includ
mdr
although
csa
inhibit
cn
fig
activ
dispens
antihbv
effect
csa
deriv
inact
cn
inhibit
fig
could
still
inhibit
hbv
infect
fig
bind
activ
site
cyp
fig
cyp
inhibit
like
respons
antihbv
activ
recent
ntcp
report
candid
entri
receptor
transport
activ
assay
show
csa
inhibit
activ
ntcp
fig
cell
fig
engin
stabli
overexpress
ntcp
previous
csa
also
suggest
bind
ntcp
membran
ligand
bind
assay
use
cell
fig
ntcp
messeng
rna
mrna
express
heparg
cell
phh
hbvsuscept
littl
express
detect
hbvnonsuscept
cell
line
includ
nonhepatocyt
hela
cell
fig
contrast
cypa
cypb
express
cell
line
irrespect
infect
suscept
intriguingli
found
inhibit
ntcp
transport
activ
correl
antihbv
entri
activ
fig
b
result
suggest
possibl
compound
target
ntcp
potenti
block
hbv
infect
test
predict
treat
heparg
cell
compound
known
inhibit
ntcp
includ
ursodeoxychol
cholic
acid
propranolol
progesteron
investig
effect
hbv
entri
use
protocol
fig
shown
fig
compound
inhibit
hbv
infect
thu
inhibit
ntcp
block
hbv
infect
also
show
cell
overexpress
ntcp
suscept
hbv
infect
fig
report
treatment
csa
also
reduc
hb
hbe
secret
cell
infect
hbv
fig
suggest
csa
inhibit
ntcpmediat
hbv
infect
bind
hbv
larg
envelop
protein
lhb
ntcp
report
import
hbv
thu
one
mechan
compound
directli
inhibit
ntcp
activ
may
block
hbv
entri
interrupt
bind
ntcp
lhb
test
possibl
establish
alphascreen
assay
evalu
lhbsntcp
bind
vitro
describ
materi
method
vitro
synthes
ntcp
lhb
least
partial
function
ntcp
bound
substrat
tca
fig
lhb
could
neutral
hbv
infect
heparg
cell
fig
shown
fig
incub
recombin
ntcp
lhb
middl
mhb
small
envelop
protein
shb
produc
signific
alphascreen
signal
fig
left
indic
direct
proteinprotein
interact
contrast
ntcp
recombin
gst
nonrelev
protein
lck
produc
bind
signal
incub
lhb
fig
suggest
alphascreen
assay
produc
specif
signal
interact
ntcp
lhb
consist
report
region
lhb
import
bind
signal
decreas
dosedepend
manner
addit
lipopeptid
fig
inact
mutant
fig
indic
competit
lhb
ntcp
bind
assay
csa
well
csa
deriv
see
next
section
shown
reduc
signal
lhbsntcp
bind
dosedepend
manner
fig
e
result
suggest
csa
target
ntcp
therebi
inhibit
interact
lhb
ntcp
consid
csa
lead
compound
test
csa
analog
antihbv
activ
shown
fig
reduc
hb
secret
hbv
infect
relat
analog
signific
antihbv
effect
fig
c
addit
analog
signific
antihbv
activ
fig
c
alisporivir
debio
antihcv
drug
also
decreas
hbv
infect
equival
level
csa
fig
figur
show
dosedepend
reduct
hb
secret
treatment
potent
antihbv
activ
csa
compar
fig
fig
result
indic
antihbv
activ
disrupt
least
chang
residu
csa
although
addit
analog
need
evalu
full
understand
structureact
relationship
notabl
alisporivir
bear
modif
residu
csa
backbon
prevent
cn
bind
immunosuppress
activ
tabl
confirm
antihbv
activ
requir
immunosuppress
activ
notabl
show
strongest
antihbv
entri
activ
among
csa
deriv
examin
data
shown
fig
median
inhibitori
concentr
antihbv
activ
well
determin
mttbase
cell
viabil
assay
shown
fig
respect
profil
superior
csa
respect
inhibit
hbv
infect
treatment
also
observ
phh
also
antihbv
effect
remark
csa
fig
result
clearli
indic
analog
csa
may
includ
compound
greater
antihbv
potenc
csa
previou
report
demonstr
csa
suppress
replic
varieti
virus
includ
human
immunodefici
viru
hcv
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
human
papillomaviru
flavivirus
vesicular
stomat
viru
vaccinia
virolog
analys
use
csa
demonstr
cyp
involv
replic
virus
studi
show
csa
inhibit
entri
hbv
appar
cypindepend
manner
previous
report
csa
suppress
hbv
replic
cell
cultur
system
carri
hbv
howev
antirepl
effect
like
respons
antihbv
activ
observ
studi
base
sever
observ
first
experiment
system
mainli
use
studi
fig
like
evalu
earli
phase
hbv
infect
hbv
replic
second
suppress
hbv
replic
csa
report
previous
mediat
block
mitochondri
permeabl
transit
pore
possibl
bind
mitochondri
antihbv
activ
shown
studi
howev
correl
bind
cyp
suggest
inhibit
hbv
infect
heparg
cell
phh
result
suppress
hbv
replic
rather
csa
inhibit
ntcp
transport
activ
disrupt
bind
ntcp
lhb
vitro
moreov
inhibit
hbv
infect
could
observ
treatment
compound
capac
inhibit
ntcp
result
suggest
target
ntcp
block
hbv
infect
current
antihbv
agent
mainli
compris
nucleo
ide
analog
ifn
develop
antihbv
agent
target
differ
molecul
greatli
need
achiev
improv
treatment
hbv
infect
especi
combat
drugresist
viru
hbv
cell
entri
mechan
poorli
defin
initi
stage
hbv
attach
target
cell
low
affin
bind
involv
cellular
factor
includ
heparan
sulfat
subsequ
entri
mechan
recent
report
ntcp
essenti
hbvspecif
although
precis
mechan
entri
intern
yet
incomplet
understood
interfer
step
emerg
attract
approach
develop
novel
therapeut
exampl
gripon
et
demonstr
peptid
mimick
region
larg
envelop
protein
prevent
hbv
infect
mous
model
result
suggest
inhibit
viru
cell
entri
could
effect
strategi
prevent
hbv
infect
achiev
clinic
outcom
postexposur
prophylaxi
blockag
vertic
transmiss
prevent
hbv
recurr
liver
transplant
given
hbv
reactiv
gener
occur
immunosuppress
uncertain
whether
clinic
relev
dose
csa
could
help
prevent
hbv
reactiv
liver
transplant
remain
also
unknown
gener
whether
entri
inhibitor
could
effect
elimin
chronic
hbv
infect
futur
studi
evalu
whether
inhibit
hbv
entri
csa
deriv
reduc
persist
hbv
infect
especi
combin
nucleo
ide
analog
interferon
studi
obtain
nonimmunosuppress
csa
deriv
could
inhibit
hbv
entri
fig
moreov
smallscal
analog
analysi
identifi
csa
deriv
exhibit
potent
inhibit
hbv
infect
fig
equival
antihcv
replic
activ
alisporivir
respect
drug
shown
reduc
hcv
viral
load
infect
patient
clinic
analog
analysi
use
csa
platform
may
identifi
potent
antihbv
compound
gener
antivir
drug
target
cellular
factor
select
drugresist
virus
lower
frequenc
directact
antivir
agent
cellular
target
relev
antihbv
drug
develop
poorli
defin
date
studi
demonstr
small
molecul
target
ntcp
inhibit
hbv
infect
studi
ntcp
inhibitor
csa
deriv
may
provid
new
antihbv
strategi
target
cellular
factor
less
like
foster
emerg
drugresist
virus
